Document is current
Any future updates will be listed below
-
Authors
Pizzuti, Laura
Barba, Maddalena
Mazzotta, Marco
Krasniqi, Eriseld
Maugeri-Saccà, Marcello
Gamucci, Teresa
Berardi, Rossana
Livi, Lorenzo
Ficorella, Corrado
Natoli, Clara
Cortesi, Enrico
Generali, Daniele
La Verde, Nicla
Cassano, Alessandra
Bria, Emilio
Moscetti, Luca
Michelotti, Andrea
Adamo, Vincenzo
Zamagni, Claudio
Tonini, Giuseppe
Sergi, Domenico
Marinelli, Daniele
Paoletti, Giancarlo
Tomao, Silverio
Botticelli, Andrea
Marchetti, Paolo
Tinari, Nicola
Grassadonia, Antonino
Valerio, Maria Rosaria
Mirabelli, Rosanna
Fabbri, Maria Agnese
D’Ostilio, Nicola
Veltri, Enzo
Corsi, Domenico
Garrone, Ornella
Paris, Ida
Sarobba, Giuseppina
Meattini, Icro
Pistelli, Mirco
Giotta, Francesco
Lorusso, Vito
Garufi, Carlo
Russo, Antonio
Cazzaniga, Marina
Del Medico, Pietro
Roselli, Mario
Vaccaro, Angela
Perracchio, Letizia
di Benedetto, Anna
Daralioti, Theodora
Sperduti, Isabella
De Maria, Ruggero
Di Leo, Angelo
Sanguineti, Giuseppe
Ciliberto, Gennaro
Vici, Patrizia
- License Information
-
More Information
Article History
Received: 22 August 2020
Accepted: 25 March 2021
First Online: 2 July 2021
Competing interests
: MB, MM, EK, MMS, RB, CF, EC, DG, AC, VA, CZ, GT, DS, DM, GP, ST, AB, NT, AG, MRV, RM, MAF, NDO, EV, DC, GS, IM, MP, FG, VL, CG, AR, PDM, MR, AV, Let Per, AdB, TD, IS, GS and GC declare no conflicts of interest. LP received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees from Roche, Pfizer, Novartis, Gentili. TG received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, Lilly. CN received travel grants/personal fees from Pfizer, Eisai, Novartis, Merck Sharp &Dohme, AstraZeneca. EB is supported by the Italian Association for Cancer Research AIRC-IG 20583; he was supported by the International Association for Lung Cancer (IASLC), the LILT (Lega Italiana per la Lotta contro I Tumori) and Fondazione Cariverona; he received speakers’ and travels’ fee from MSD, Astra-Zeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche; consultant’s fee from Roche, Pfizer; institutional research grants from Astra-Zeneca, Roche. LM received advisory board from Roche. AM received travel grants from Eisai, Celgene, Novartis Ipsen; personal fees, advisory boards from EISAI, Novartis, Astra Zeneca, Teva, Pfizer, Celgene. MC received personal fees, advisory boards from Pierre Fabre, Astra Zeneca, Celgene, Eisai, Novartis, Lilly. NLV received personal fees from Eisai and Novartis; research funding from Eisai, travel grants from Pfizer, Roche, Gentili; consulting role from Celldex. PM has/had a consultant/advisory role for BMS, Roche Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre Fabre, and Incyte. IP received personal fees/advisory boards from Roche, Pfizer, Novartis, Italfarmaco, Gentili, Pierre Fabre. OG received personal fees from Celgene, Novartis, Eisai; research funding from Eisai, consulting activities with Celgene, Eisai, Pfizer, Amgen. RDM declares to be a scientific advisory board member at ExosomicsSpA (Siena IT), Hibercell Inc. (New York, NY), Kiromic Inc. (Houston, TX) and at Exiris Inc. (Rome, IT). ADL received consulting fees from Novartis and Roche. PV received travel grants from Eisai, Roche, Pfizer, Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili.
